Delivering you the very latest breakthroughs and results from an ever expanding number of protein molecules in development and offers you the best opportunity to learn from worldrenowned academics and industry visionaries. This is the industry\’s most comprehensive conference for sharing new ideas to accelerate the discovery, engineering and development of alternative scaffolds and novel protein therapeutics to create differentiated drugs.

Complete Brochure Now Available
» Download Today!

\’Again, an extremely useful update on the next wave of targeted protein therapies, well done\’ – Fredrik Frejd, Vice President, Research, Affibody

By Attending You Will:

• Case Studies on the successful delivery of therapeutics that cross the blood-brain barrier, immunotherapies, and difficult clinical targets
• Profit from learnings on design, development and approval of bispecifics and multispecific proteins
• Hear the latest data and clinical breakthroughs for scaffolds, antibody fragments, peptides, and immunotherapies

\’An all-encompassing smorgasbord to provide a really comprehensive update on what is happening in the biologics space\’ – Catherine Hutchings, Principal Scientist, Antibody Discovery, Heptares Therapeutics

Keynote Presentations

Potent Antibody Drug Conjugates for Cancer Therapy
Peter Senter, Ph.D.
Vice President, Chemistry
Seattle Genetics

Bispecific Antibodies – Are We There Yet?
Paul J. Carter, Ph.D.
Staff Scientist and Senior Director, Antibody Engineering
Genentech, Inc.

New Engineering and Application Perspectives of Scaffold Proteins
Andreas Plückthun, Ph.D.
Director, Department of Biochemistry
University of Zurich, Switzerland

Development of Bite® Antibody Construct Blinatumomab – The First FDA-Approved Bispecific Antibody
Patrick Baeuerle
Vice President, Research; General Manager
Amgen Research GmbH, Germany

Engineered Proteins for Signaling
Jim Wells, Ph.D.
Professor and Chair, Pharmaceutical Chemistry
UCSF

Receptor-Mediated Delivery of Bispecific Antibodies into the Primate Brain: Challenges and Safety Findings
Mark Dennis, Ph.D.
Principal Scientist, Antibody Engineering
Genentech, Inc.

\’This conference is one of the best IBC conferences I have ever attended. I like the new ideas and active discussions in the meeting\’ – Liang Tang, Principal Scientist, Bayer Healthcare